You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》招銀國際升康方生物(09926.HK)目標價至59.1元 期待今年再豐收
阿思達克 03-21 16:50
招銀國際發表報告,將康方生物(09926.HK)目標價由51.23元上調至59.61元,維持「買入」評級。公司去年收入45.3億元人民幣,包括16.3億元人民幣產品銷售收入,及29.2億元人民幣AK112相關的許可權收入。產品毛利率維持在91.8%的高水平,整體銷售開支佔銷售額比率由74.5%降至56.3%,反映營運效益改善。研發開支減少5.2%,純利20.3億元人民幣。於去年底,持有充裕現金49億元人民幣。 該行相信今年是另一個豐收年,當中AK104及AK112有成功的潛力,非腫瘤科業務接近商業化,多種藥物正在進行評估中。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account